Study guide

3.4 Polycythemia & Erythrocytosis Classification

ASCP Hematology Technologist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Hematopoiesis & Cellular Physiology

1.1 Hematopoiesis, Bone Marrow Microenvironment & Growth Factors 1.2 Erythrocyte Physiology, Metabolism & Destruction Pathways 1.3 Leukocyte Kinetics, Morphology & Phagocytic Function 1.4 Platelet Physiology, Ultrastructure & Thrombopoiesis

2 Chapter 2: Erythrocyte Disorders & Non-Hemolytic Anemias

2.1 Iron Metabolism & Iron Deficiency Anemia 2.2 Anemia of Chronic Inflammation, Sideroblastic Anemias & Lead Toxicity 2.3 Hemoglobinopathies & Qualitative Globin Chain Defects 2.4 Alpha and Beta Thalassemias 2.5 Megaloblastic, Macrocytic & Hypoproliferative Anemias

3 Chapter 3: Hemolytic Anemias & Erythrocytosis

3.1 Intrinsic Hemolytic Anemias: Membrane & Metabolic Defects 3.2 Immune-Mediated Hemolytic Anemias & Paroxysmal Nocturnal Hemoglobinuria 3.3 Non-Immune Extrinsic Hemolytic Anemias & Microangiopathies 3.4 Polycythemia & Erythrocytosis Classification

4 Chapter 4: Benign Leukocyte Alterations, Acute Leukemias & Bone Marrow Evaluation

4.1 Quantitative Leukocyte Alterations, Toxic Change & Leukemoid Reaction 4.2 Inherited Leukocyte Anomalies, Reactive Lymphocytosis & Storage Disorders 4.3 Acute Myeloid Leukemia (AML) & Related Neoplasms 4.4 Acute Lymphoblastic Leukemia (ALL) & Precursor Lymphoid Neoplasms 4.5 Bone Marrow Examination, Differential & M:E Ratio Assessment

5 Chapter 5: Chronic Myeloid Neoplasms, MDS & Mature Lymphoid Neoplasms

5.1 Myelodysplastic Syndromes (MDS) & Overlap Syndromes 5.2 Chronic Myeloproliferative Neoplasms (CML, PV, ET, PMF) 5.3 Chronic Lymphocytic Leukemia & Indolent B-Cell Lymphomas 5.4 Aggressive Lymphomas, Hodgkin Lymphoma & Mature T-Cell Disorders 5.5 Plasma Cell Neoplasms & Monoclonal Gammopathies

6 Chapter 6: Hemostasis: Primary, Secondary & Fibrinolytic Systems

6.1 Primary Hemostasis, Platelet Receptors & Qualitative Platelet Disorders 6.2 Quantitative Platelet Disorders & Immune Thrombocytopenias 6.3 The Coagulation Cascade & Cell-Based Hemostatic Model 6.4 Fibrinolytic System, Natural Anticoagulants & Thrombophilia

7 Chapter 7: Factor Deficiencies, Coagulation Testing & Anticoagulation

7.1 Hereditary Coagulation Factor Deficiencies & von Willebrand Disease 7.2 Acquired Coagulation Factor Deficiencies, Circulating Inhibitors & DIC 7.3 Routine and Specialized Coagulation Testing & Mixing Study Interpretation 7.4 Anticoagulant Therapies, Laboratory Monitoring & Reversal Strategies 7.5 Viscoelastic Testing, Heparin Neutralization & Chromogenic Assays

8 Chapter 8: Hematology Laboratory Testing & Advanced Diagnostics

8.1 Automated Hematology Analyzers, Interference Flags & Manual Methods 8.2 Cytochemical Staining, Flow Cytometry & Molecular Diagnostics 8.3 Erythrocyte Sedimentation Rate, Hemolytic Indicators & Special Erythrocyte Studies 8.4 Cerebrospinal Fluid Analysis, Cell Counts & Cytology 8.5 Serous Effusions & Synovial Fluid Analysis

9 Chapter 9: Laboratory Operations, Quality Assessment & Safety

9.1 The Total Testing Process: Preanalytical, Analytical & Postanalytical Quality 9.2 Quality Control Statistics, Levey-Jennings Charts & Westgard Multirules 9.3 Laboratory Mathematics: Dilutions, Concentration, Molarity & Standard Curves 9.4 Method Evaluation, Diagnostic Statistics & Point-of-Care Testing 9.5 Regulatory Framework, Proficiency Testing & Competency Assessment 9.6 Laboratory Safety: Bloodborne Pathogens, Personal Protective Equipment & Chemical Hygiene 9.7 Emergency Response, Spill Management & Specimen Packaging and Transport 9.8 Hematology Instrumentation: Microscopy, Counters, Analyzers & Centrifuges

3.4 Polycythemia & Erythrocytosis Classification

Key Takeaways Explain This Topic AI

Erythrocytosis is classified as Relative (hemoconcentration with normal red cell mass and contracted plasma volume) or Absolute (true increase in red cell mass).

Primary Polycythemia (Polycythemia Vera) is a clonal myeloproliferative neoplasm characterized by panmyelosis, suppressed/low serum erythropoietin (EPO), and a JAK2 V617F (>95%) or exon 12 mutation.

Secondary erythrocytosis is driven by elevated or inappropriately normal serum EPO: physiologically appropriate in hypoxia (COPD, cyanotic heart disease, high altitude, high-affinity hemoglobins) vs inappropriate in autonomous EPO secretion (renal cell carcinoma, HCC, uterine fibroids, PKD).

Smoker's polycythemia combines elevated carboxyhemoglobin (left-shifting the oxygen-dissociation curve and creating functional hypoxia) with nicotine-induced plasma volume contraction.

The diagnostic algorithm begins with confirming absolute erythrocytosis, followed by serum EPO quantification; low EPO indicates PV and directs JAK2 testing, whereas high EPO directs cardiopulmonary, p50, and renal imaging evaluations.

Last updated: August 2026

Polycythemia & Erythrocytosis Classification

Erythrocytosis (or polycythemia) is defined as an abnormal elevation in red blood cell parameters: hemoglobin ( > 16.5 g/dL >16.5\text{ g/dL} > 16.5 g/dL in men, > 16.0 g/dL >16.0\text{ g/dL} > 16.0 g/dL in women), hematocrit ( > 49 % >49\% > 49% in men, > 48 % >48\% > 48% in women), or red blood cell count ( > 5.8 × 10 12 / L >5.8 \times 10^{12}/\text{L} > 5.8 × 1 0 12 / L in men, > 5.2 × 10 12 / L >5.2 \times 10^{12}/\text{L} > 5.2 × 1 0 12 / L in women). Precise clinical classification is essential to distinguish benign hemoconcentration from life-threatening clonal myeloproliferative neoplasms and occult neoplasms. CLASSIFICATION OF ERYTHROCYTOSIS

  • |
  • +-------------------------------+-------------------------------+
  • | |
  • RELATIVE ERYTHROCYTOSIS ABSOLUTE ERYTHROCYTOSIS
  • Normal Red Cell Mass - True Increased Red Cell Mass
  • Decreased Plasma Volume - Elevated Hb / Hct / RBC Count
  • Dehydration, Gaisböck Syndrome |
  • +-------------------------------+-------------------------------+
  • | |
  • PRIMARY POLYCYTHEMIA SECONDARY ERYTHROCYTOSIS
  • (Polycythemia Vera - MPN) - Elevated / Normal EPO
  • LOW / SUPPRESSED EPO - JAK2 Mutation NEGATIVE
  • JAK2 V617F (>95%) / Exon 12 |
  • Panmyelosis (RBC + WBC + Plt) +-------------------------------+-------------------------------+
  • | |
  • PHYSIOLOGICALLY APPROPRIATE INAPPROPRIATE (AUTONOMOUS)
  • (Hypoxia-Driven EPO Elevation) (Non-Hypoxic EPO Secretion)
  • Altitude, COPD, Cyanotic Heart - Renal Cell Carcinoma (RCC)
  • Smoker's Polycythemia (COHb) - Hepatocellular Carcinoma
  • High-Affinity Hemoglobins (Low p50) - Polycystic Kidney Disease
  • 1. Relative vs. Absolute Erythrocytosis
  • Relative Erythrocytosis (Spurious / Apparent)

Pathophysiology : Total red blood cell mass (RCM) is completely normal , but plasma volume is markedly decreased (contracted), resulting in artifactual hemoconcentration.

Etiologies :

Acute Dehydration : Severe vomiting, diarrhea, excessive diaphoresis, severe burns, or aggressive diuretic therapy.

Gaisböck Syndrome (Stress Erythrocytosis / Pseudopolycythemia) : Characteristically observed in middle-aged, hypertensive, obese, anxious men who smoke heavily; associated with chronic contracted plasma volume and elevated hematocrit without true red cell mass expansion.

Absolute Erythrocytosis

Pathophysiology : True, biological expansion of the total circulating red blood cell mass exceeding 125 % 125\% 125% of predicted normal. Absolute erythrocytosis is subclassified into Primary (autonomous stem cell proliferation) and Secondary (growth factor / EPO driven).

  • 2. Primary Polycythemia: Polycythemia Vera (PV)
  • Molecular Pathogenesis & The JAK2 Mutation

Polycythemia Vera is a clonal Myeloproliferative Neoplasm (MPN) originating in a multipotent hematopoietic stem cell. The hallmark molecular driver is a somatic mutation in the Janus Kinase 2 ( JAK2 ) gene:

J A K 2 V617F JAK2\text{ V617F} J A K 2 V617F Point Mutation (Exon 14) : Present in > 95 % >95\% > 95% of PV cases. A substitution of valine for phenylalanine at codon 617 in the JH2 pseudokinase (regulatory) domain abolishes auto-inhibition, locking the JAK2 tyrosine kinase into a constitutively active, ligand-independent firing state .

J A K 2 Exon 12 JAK2\text{ Exon 12} J A K 2 Exon 12 Mutations : Present in 3 – 4 % 3\text{--}4\% 3 – 4% of PV cases (particularly in younger patients presenting with isolated erythrocytosis without prominent leukocytosis or thrombocytosis).

Signal Transduction : Constitutive JAK2 phosphorylation persistently activates downstream STAT5, PI3K/Akt, and MAPK signaling pathways, driving uncontrolled erythroid, myeloid, and megakaryocytic proliferation independent of exogenous erythropoietin. JAK2 V617F Mutation in JH2 Regulatory Domain

  • -> Loss of Auto-Inhibitory Control
  • -> Constitutive Tyrosine Kinase Phosphorylation (Ligand-Independent)
  • -> Continuous Activation of STAT5, PI3K/Akt, and MAPK Pathways
  • -> Panmyelosis in Bone Marrow
  • -> Hyperviscosity, Thrombosis, & Massive Systemic Red Cell Expansion
  • -> Negative Feedback Loops Suppress Renal EPO Secretion (LOW SERUM EPO)
  • WHO Diagnostic Criteria for Polycythemia Vera

Diagnosis requires meeting all 3 major criteria, or the first 2 major criteria plus the minor criterion: MAJOR CRITERIA:

  • 1. Hemoglobin >16.5 g/dL (men) or >16.0 g/dL (women), OR
  • Hematocrit >49% (men) or >48% (women), OR
  • Increased red cell mass (>25% above mean normal predicted)
  • 2. Bone marrow biopsy showing hypercellularity for age with trilineage growth
  • (panmyelosis: prominent erythroid, granulocytic, and pleomorphic megakaryocytic proliferation)
  • 3. Presence of JAK2 V617F or JAK2 exon 12 mutation

MINOR CRITERION:

  • Subnormal / Suppressed Serum Erythropoietin (EPO) level
  • Clinical and Laboratory Hallmarks of PV

Suppressed Serum EPO : Because erythroid expansion is driven autonomously by mutant JAK2 signaling, physiological negative feedback suppresses renal EPO synthesis, resulting in subnormal or undetectable serum EPO ( < 4 mU/mL <4\text{ mU/mL} < 4 mU/mL ). This is the single most important biochemical distinction from secondary polycythemia.

Panmyelosis on CBC : Elevated RBC count ( 6.0 – 10.0 × 10 12 / L 6.0\text{--}10.0 \times 10^{12}/\text{L} 6.0 – 10.0 × 1 0 12 / L ), leukocytosis ( 12.0 – 25.0 × 10 9 / L 12.0\text{--}25.0 \times 10^9/\text{L} 12.0 – 25.0 × 1 0 9 / L with neutrophilia and basophilia), and thrombocytosis ( 450 – 1000 × 10 9 / L 450\text{--}1000 \times 10^9/\text{L} 450 – 1000 × 1 0 9 / L ).

Leukocyte Alkaline Phosphatase (LAP / NAP Score) : Characteristically elevated ( > 100 >100 > 100 , often 150 – 250 150\text{--}250 150 – 250 ) , reflecting mature granulocytic activation (in contrast to Chronic Myeloid Leukemia where LAP is low/zero).

Clinical Manifestations :

Hyperviscosity Syndrome : Headache, dizziness, visual scotomas, tinnitus, and angina.

Aquagenic Pruritus : Severe, intractable itching after contact with warm water (without a rash), mediated by mast cell and basophil degranulation.

Thrombosis (Arterial and Venous) : Leading cause of morbidity; includes stroke, myocardial infarction, and deep vein thrombosis at unusual sites (Budd-Chiari syndrome, mesenteric thrombosis).

Splenomegaly : Present in ≈ 70 % \approx 70\% ≈ 70% of patients due to extramedullary hematopoiesis.

Plethoric "Ruddy" Complexion & Erythromelalgia : Burning pain and erythema in the hands and feet caused by microvascular platelet occlusion.

3. Secondary Erythrocytosis

Secondary erythrocytosis is driven by elevated or inappropriately normal serum erythropoietin (EPO) acting on normal, non-clonal hematopoietic progenitors. The J A K 2 JAK2 J A K 2 mutation is negative , and panmyelosis is absent (WBC and platelets are normal). SECONDARY ERYTHROCYTOSIS PATHWAYS

  • |
  • +------------------------------+------------------------------+
  • | |
  • PHYSIOLOGICALLY APPROPRIATE PHYSIOLOGICALLY INAPPROPRIATE
  • (Hypoxia-Driven EPO Production) (Autonomous EPO Hypersecretion)
  • | |
  • Renal Hypoxia Stabilizes HIF-1alpha Tumor / Tissue Overproduces EPO
  • -> Transcribes Renal EPO Gene Directly Without Hypoxia
  • -> High Serum EPO Stimulates Marrow --> High Serum EPO Stimulates Marrow
  • 1. Physiologically Appropriate (Hypoxia-Driven Secondary Erythrocytosis)

Renal interstitial peritubular fibroblasts monitor tissue oxygen tension ( p O 2 pO_2 p O 2 ​ ). Under hypoxic conditions, prolyl hydroxylases cannot hydroxylate Hypoxia-Inducible Factor 1 α \alpha α ( H I F - 1 α HIF\text{-}1\alpha H I F - 1 α ) . Non-hydroxylated H I F - 1 α HIF\text{-}1\alpha H I F - 1 α escapes proteasomal degradation, accumulates, heterodimerizes with H I F - 1 β HIF\text{-}1\beta H I F - 1 β , translocates to the nucleus, and activates transcription of the erythropoietin ( EPO ) gene.

High Altitude Acclimatization : Low ambient atmospheric p O 2 pO_2 p O 2 ​ .

Chronic Pulmonary Diseases : Severe Chronic Obstructive Pulmonary Disease (COPD), diffuse interstitial pulmonary fibrosis, obesity-hypoventilation syndrome, and obstructive sleep apnea (OSA).

Cyanotic Congenital Heart Disease : Right-to-left shunts (e.g., Tetralogy of Fallot, Eisenmenger syndrome).

Smoker's Polycythemia (Carboxyhemoglobinemia) : Cigarette smoke contains carbon monoxide ( C O CO CO ), which binds to hemoglobin with an affinity 210 times greater than oxygen , generating carboxyhemoglobin (COHb) . COHb cannot bind oxygen and allosterically locks the remaining three heme groups in the high-affinity relaxed (R) state, shifting the oxygen-dissociation curve to the left . This causes profound tissue hypoxia and compensatory EPO elevation, combined with nicotine-induced plasma volume contraction.

High-Affinity Hemoglobin Variants : Globin chain mutations (e.g., Hb Chesapeake, Hb Yakima, Hb Malmö, Hb Montefiore ) alter the α 1 β 2 \alpha_1\beta_2 α 1 ​ β 2 ​ contact interface, preventing transition from the high-affinity R state to the low-affinity T state. The oxygen-dissociation curve is severely shifted to the left , characterized by a markedly decreased P 50 P_{50} P 50 ​ (the partial pressure of O 2 O_2 O 2 ​ at which hemoglobin is 50% saturated; normal P 50 ≈ 26.6 mmHg P_{50} \approx 26.6\text{ mmHg} P 50 ​ ≈ 26.6 mmHg , in high-affinity variants P 50 < 18 mmHg P_{50} < 18\text{ mmHg} P 50 ​ < 18 mmHg ). The kidney senses pseudohypoxia and hypersecretes EPO.

Congenital Methemoglobinemia : Oxidation of iron to F e 3 + Fe^{3+} F e 3 + prevents O 2 O_2 O 2 ​ transport and left-shifts the ODC.

2. Physiologically Inappropriate (Autonomous EPO Hypersecretion)

Renal or extra-renal tissues autonomously produce EPO independent of physiological oxygen tension:

Renal Neoplasms & Structural Lesions :

Renal Cell Carcinoma (RCC) : Classic EPO-secreting malignancy.

Polycystic Kidney Disease (PKD) and Hydronephrosis : Expanding cysts compress adjacent peritubular capillaries, generating localized, false renal ischemia that triggers massive focal EPO secretion despite normal systemic oxygenation.

Renal Artery Stenosis : Unilateral renal hypoperfusion drives excessive EPO synthesis.

Extra-Renal Autonomous Tumors :

Hepatocellular Carcinoma (HCC) (~5–10% secrete EPO).

Cerebellar Hemangioblastoma (vascular tumor producing EPO).

Uterine Leiomyomas (Fibroids) (large fibroids producing autonomous erythropoietin).

Pheochromocytoma and Adrenal Cortical Tumors .

Exogenous Administration : Recombinant human erythropoietin (rhEPO/darbepoetin) abuse (blood doping in athletes) or androgen/testosterone therapy (stimulates renal EPO synthesis and direct bone marrow erythropoiesis).

4. Comprehensive Differential Diagnostic Comparison

Diagnostic Parameter Relative Erythrocytosis Polycythemia Vera (Primary) Hypoxic Secondary Erythrocytosis Autonomous Secondary Erythrocytosis

  • Red Cell Mass Normal Markedly Increased Increased Increased
  • Plasma Volume Decreased Normal to Increased Normal Normal
  • Serum EPO Level Normal LOW / SUPPRESSED (<4 mU/mL) ELEVATED (>20 mU/mL) ELEVATED (>20 mU/mL)
  • J A K 2 V617F JAK2\text{ V617F} J A K 2 V617F Mutation Negative POSITIVE (>95%) Negative Negative

Arterial Oxygen ( S a O 2 SaO_2 S a O 2 ​ ) Normal ( > 95 % >95\% > 95% ) Normal ( > 95 % >95\% > 95% ) Decreased ( < 92 % <92\% < 92% ) Normal ( > 95 % >95\% > 95% )

P 50 P_{50} P 50 ​ (ODC Affinity) Normal ( 26.6 mmHg 26.6\text{ mmHg} 26.6 mmHg ) Normal Normal (or Low if High-Affinity Hb) Normal

  • WBC Count Normal Elevated (Neutrophilia/Basophilia) Normal Normal
  • Platelet Count Normal Elevated ( > 450 × 10 9 / L >450 \times 10^9/\text{L} > 450 × 1 0 9 / L ) Normal Normal
  • LAP / NAP Score Normal Elevated ( > 100 >100 > 100 ) Normal Normal
  • Splenomegaly Absent Present (~70%) Absent Absent

Bone Marrow Findings Normal Trilineage Hyperplasia (Panmyelosis) Pure Erythroid Hyperplasia Pure Erythroid Hyperplasia

Loading diagram... Erythrocytosis Stepwise Diagnostic Algorithm